RA0069

antibody from Oursmab

Targeting: CD19

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0069

Provider

Oursmab

Product name

Budoprutug (Biosimilar Reference Antibody) (CD19)

Antibody type

Monoclonal

Description

Budoprutug is a human IgG1 kappa monoclonal antibody. It is designed as a targeted therapeutic agent specifically aimed at the CD19 antigen. Its primary mechanism of action is to induce the death of malignant B cells that express this antigen by binding to CD19. As an IgG1 isotype antibody, it possesses potent immune effector functions, enabling it to mediate the clearance of B cells through Antibody-Dependent Cellular Cytotoxicity (ADCC) and/or Complement-Dependent Cytotoxicity (CDC). Budoprutug is investigated for the treatment of B cell malignancies, such as Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), with the goal of eliminating the cancerous B cell population in the body.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.